Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Responsible AI for Personalized Patient Education and Engagement Across Medical Conditions: Leveraging Multi-Agent LLMs, Ambient Technology, and NotebookLM-A Case Study in Diabetes Education and Limb Preservation.

Journal of the American Podiatric Medical Association·2026
Same author

Biomarkers in Alzheimer's disease clinical trials: 2025.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects Modeling.

Annals of neurology·2026
Same author

Exploring regional BOLD fluctuations to understand the pathophysiology of mild cognitive impairments in individuals with Parkinson's disease.

Parkinsonism & related disorders·2026
Same author

Comparing clinical features of behavioral variant frontotemporal dementia and Alzheimer's disease using network analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

ACC Reward Location Information Is Carried by Hippocampal Theta Synchrony and Suppressed in a Type 2 Diabetes Model.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2025
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

MayaRae N Mugosa1, Jefferson W Kinney2, Lorenzo Gabriel Pasia3

  • 1UNLV, Las Vegas, NV, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

这项研究探讨了阿尔茨海默病 (AD) 进展的血液生物标志物. 虽然在统计学上并不显著,但趋势表明酸化-217 (pTau217) 可能是跟踪AD的有价值生物标志物.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 生物化学 生化学
  • 神经科学是一个神经科学.
  • 生物标志物发现发现

背景情况:

  • 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知和日常功能.
  • 早期诊断和监测AD进展对于有效管理至关重要.
  • 目前的AD诊断工具往往是侵入性的和昂贵的;血液生物标志物提供了一个可扩展的替代方案.

研究的目的:

  • 为了评估质纤维酸蛋白 (GFAP),酸化-181 (ptau181) 和酸化-217 (pTau217) 的血度.
  • 评估这些生物标志物的潜力,在两年内跟踪阿尔茨海默病的进展.

主要方法:

  • 使用SIMOA Quanterix仪器测量了GFAP和ptau181的血度.
  • 在Lumipulse G1200平台上使用化学发光酶免疫试验 (CLEIA) 测量了pTau217的血度.
  • 进行了纵向分析,以确定随着时间的推移生物标志物度的趋势.

主要成果:

  • 纵向分析表明,在两年内,一些候选生物标志物的度逐渐增加.
  • 在研究期间,在疾病状态之间没有观察到生物标志物水平的统计学上显著差异.
  • 趋势表明潜在的效用,尽管需要更大的样本大小来进行统计验证.

结论:

  • 生物标志物度的观察趋势需要在更大的队列中进行进一步的研究.
  • 化陶-217 (pTau217) 是阿尔茨海默病进展的生物标志物,因为它与粉样蛋白状况的相关性.
  • 建议继续对pTau217的研究,因为它在AD诊断和监测中的潜力.